Moreover, anti-tumor necrosis factor (TNF) α treatment seems to reduce the ability of platelets to bind to and activate leukocytes in RA, which may decrease the risk of thrombotic events [24, 25]. This evidence concerns the gene TNF and rheumatoid arthritis.